Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Aug 17;15(8):e43671.
doi: 10.7759/cureus.43671. eCollection 2023 Aug.

Compassionate Use of Remdesivir in Pregnancy: A Case Series From a COVID-19 Dedicated Center and Review of Literature

Priyanka Sharma  1 , Priyanka Gupta  2 , Rashmi Virmani  3 , Anil Pandey  4 , Jagadish C Sharma  1 , Avir Sarkar  1
Affiliations
Case Reports

Compassionate Use of Remdesivir in Pregnancy: A Case Series From a COVID-19 Dedicated Center and Review of Literature

Priyanka Sharma et al. Cureus. .

Abstract

Pregnancy is associated with immunological changes that could render an individual vulnerable to the severe coronavirus disease 2019 (COVID-19) disease. Even as we witnessed the third and most widespread pandemic wave, a conclusively advantageous treatment option still remained elusive. Remdesivir was one of the front-running therapeutic options that received emergency use authorization (EUA) and subsequent approval for the management of moderate to severe COVID-19 infections. Here, we report a series of moderate to severe COVID-19-infected pregnancies and the experience of remdesivir use on a compassionate basis. Four cases of pregnancy complicated with moderate to severe COVID-19 infections where remdesivir was administered were recruited into the study, and their outcome was assessed objectively. Of these cases, three women received remdesivir in addition to standard SARS-CoV-2 treatment in the antenatal period. One woman received remdesivir after delivery. One woman received tocilizumab in addition to remdesivir and standard SARS-CoV-2 care. Two women survived and were subsequently discharged to home care. Two succumbed to the disease. One baby who was exposed to remdesivir in utero is doing well at six months post-delivery. Remdesivir had been granted EUA for the treatment of suspected or laboratory-confirmed COVID-19 infection in adults and children who were hospitalized with severe disease or requiring supplemental oxygen and mechanical ventilation or extracorporeal membrane oxygenation (ECMO) in May 2020. This issuance allowed the use of the same dosing regimen in pregnant and parturient women as in the general adult population. Thus, this series of cases tried to assess the outcome of this drug among COVID-19-infected pregnant women. Early initiation of remdesivir in pregnancy in the viremic phase seems to provide some advantages in the survival outcome. Its use may be associated with transient elevation in hepatic transaminases in some cases. No detrimental effects on the ongoing pregnancies, fetuses, or neonates have been observed. Further large-scale studies may provide more conclusive evidence.

Keywords: covid-19; pregnancy; prone positioning; remdesivir; sars-cov-2; tocilizumab.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Clinical timeline of case 1.
SF ratio = SpO2/FiO2; NEW Score = National Early Warning Score
Figure 2
Figure 2. Clinical timeline of Case 2.
SF ratio = SpO2/FiO2; NEW Score: National Early Warning Score
Figure 3
Figure 3. Clinical timeline of Case 3.
SF ratio = SpO2/FiO2; NEW Score: National Early Warning Score
Figure 4
Figure 4. Key for Clinical Intervention and Outcome.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Higher severe acute respiratory syndrome coronavirus 2 infection rate in pregnant patients. Lokken EM, Taylor GG, Huebner EM, et al. Am J Obstet Gynecol. 2021;225:75. - PMC - PubMed
    1. Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study. Knight M, Bunch K, Vousden N, et al. BMJ. 2020;369:0. - PMC - PubMed
    1. A scoping review of the pathophysiology of COVID-19. Marik PE, Iglesias J, Varon J, Kory P. Int J Immunopathol Pharmacol. 2021;35:20587384211048026. - PMC - PubMed
    1. World Health Organization. WHO Coronavirus (COVID 19) Dashboard. [ Feb; 2022 ]. 2020. https://coronavirus/vaccine/summary-of-yellow-card-reporting/files/COVID... https://coronavirus/vaccine/summary-of-yellow-card-reporting/files/COVID...
    1. Management of coronavirus disease 2019 (COVID-19) pneumonia. Thirkell P, Griffiths M, Waller MD. Encyclopedia of Respiratory Medicine. 2021:342–349.

Publication types

LinkOut - more resources